8 results about "Keratoconjunctivitis" patented technology

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of medicines for treating ophthalmic diseases. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials: flos chrysanthemi, concha haliotidis, semen cassiae torae, honey-fried licorice root and a component A, wherein the component A is selected from at least one of herba schizonepetae, radix puerariae and herba menthae. The composition has the effects of removing heat from the liver and purging heat, and treating red and astringent eye pain, and experiments show that the composition can improve the tear secretion amount, prolong the tear film rupture time and / or protect the corneal epithelium. The traditional Chinese medicine composition can be clinically used for treating dry eyes, asthenopia, keratoconjunctivitis, cataract and vitreous opacity.

The present disclosure relates to heterogeneous cell compositions derived from canine or feline uterine tissue and methods of producing and use thereof. In some aspects, the heterogeneous cell compositions comprise a mixture of mesenchymal progenitor cells and epithelial progenitor cells. In some aspects, the heterogeneous cell compositions are used as an autologous or allogeneic treatment for the treatment of diseases such as chronic kidney disease, atopic dermatitis, immune mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune mediated polyarthritis or wounds in canines and felines.

Keratoconjunctivitis sicca is a general term of a plurality of diseases which are accompanied by eye discomfort and (or) ocular surface tissue lesion characteristics and are caused by tear quality or quantity abnormality or dynamic abnormality caused by any reason, and belongs to the field of chronic keratoconjunctivitis in western medicine. The common symptoms comprise eye dryness, easy fatigue, eye itching, foreign body sensation, burning pain, secretion viscosity, wind afraid, photophobia, lacrimation and external stimulation sensitivity; the two eyes of a patient with serious diseases in the later stage are red and swollen, hyperemia and keratinization, corneal epithelium exfoliation and filament adhesion exist, keratoconjunctival lesion can be caused if the patient is injured for a long time, and the continuous development of the keratoconjunctival lesion possibly causes irreversible influence on vision. The traditional Chinese medicine composition is characterized by being prepared from the following raw material medicines in parts by mass: 100 to 1000 parts of radix rehmanniae, 100 to 1000 parts of radix ophiopogonis, 100 to 1000 parts of herba dendrobii, 100 to 1000 parts of bulbus lilii, 100 to 1000 parts of radix polygonati officinalis and 200 to 500 parts of flos chrysanthemi. Corresponding auxiliary materials can also be added into the traditional Chinese medicine composition to prepare clinically common tablets, granules and oral dosage forms.

The present application provides compositions and methods for reducing tear evaporation and for treatment of dry eye diseases. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, medium chain triglycerides, propylene glycol diacetate, and combinations thereof, wherein the topical ophthalmological composition is free from any other active pharmaceutical compound useful for the treatment of dry eye disease, dry eye syndrome, meibomian gland disfunction, or keratoconjunctivitis sicca. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of dry eye disease, dry eye syndrome, meibomian gland disfunction, keratoconjunctivitis sicca, and methods for reducing or modifying tear evaporation rate, increasing tear retention time, protecting tear film, preventing tear evaporation, producing a soothing effect, or improving tear quality in an eye of a subject.

The present application provides compositions and methods for treating ocular conditions (e.g., dry eye syndrome, dry eye disease, keratoconjunctivitis sicca, inflammatory dry eye, redness, or meibomian gland dysfunction). The compositions can comprise a transient receptor potential melastatin 8 (TRPM8) agonist (e.g., menthol or AR-15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide)) and a semi-fluorinated alkane compound; or can comprise a TRPM8 agonist (e.g., menthol AR-15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide)), a semi-fluorinated alkane compound. The compositions can confer chemical stability of the TRPM8 agonist.

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and / or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and / or conjunctiva, and / or to the Meibomian gland.